Biohaven Pharmaceutical (NYSE: BHVN) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Biohaven Pharmaceutical to related companies based on the strength of its profitability, valuation, earnings, analyst recommendations, dividends, risk and institutional ownership.
Institutional & Insider Ownership
47.8% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 49.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Biohaven Pharmaceutical and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Biohaven Pharmaceutical Competitors||663||2472||6707||135||2.63|
Biohaven Pharmaceutical currently has a consensus target price of $38.00, indicating a potential upside of 43.72%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.36%. Given Biohaven Pharmaceutical’s stronger consensus rating and higher probable upside, equities analysts plainly believe Biohaven Pharmaceutical is more favorable than its rivals.
This table compares Biohaven Pharmaceutical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Biohaven Pharmaceutical Competitors||-4,446.04%||-474.52%||-42.18%|
Earnings & Valuation
This table compares Biohaven Pharmaceutical and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Biohaven Pharmaceutical||N/A||-$63.67 million||-5.07|
|Biohaven Pharmaceutical Competitors||$217.40 million||-$39.40 million||-56.59|
Biohaven Pharmaceutical’s rivals have higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Biohaven Pharmaceutical beats its rivals on 7 of the 12 factors compared.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.